Gut Bacterium Colon Cancer Mystery Solved by Hopkins

Scientists have cracked a gut bacterium colon cancer mystery that sat unsolved for almost twenty years, and the answer is a surprisingly ordinary protein. A team at Johns Hopkins says the toxin from a common microbe needs a docking point on colon cells before it can do any harm, and they already built a decoy that blocked it in mice.

The bug living in your gut

The microbe is called Bacteroides fragilis, and according to ScienceDaily, it can be found in the intestines of up to twenty percent of healthy people. Having it does not mean you will get cancer. Only certain strains make a toxin known as BFT, an enzyme that cuts proteins like a pair of molecular scissors.

That toxin has been a suspect for a long time. In a landmark study from 2009, the same Johns Hopkins group showed that BFT could help colon tumors form. It damages a protein called E-cadherin, which holds neighbouring cells together and keeps the gut lining sealed, and a leaky lining invites inflammation.

The missing link, found with CRISPR

Here is the puzzle that stumped everyone. BFT breaks E-cadherin, yet it does not stick to E-cadherin directly. Something else had to be helping it land, and repeated attempts to find that helper failed.

The team, published in the journal Nature, finally used a genome-wide CRISPR screen. Maxwell White, an M.D./Ph.D. candidate in the lab of senior author Cynthia Sears, switched off genes in colon lining cells one by one to see which ones the toxin needed. One gene stood out. It makes claudin-4, a protein that helps form tight junctions, the seals between cells.

"Claudin-4 was a clear, resounding top hit," White said, according to the ScienceDaily write-up of the Johns Hopkins release. When claudin-4 was disabled, the toxin could no longer attach, and E-cadherin stayed intact.

Why the answer surprised researchers

Scientists had expected a signaling receptor, the kind of switch cells use to react to messages from outside. Claudin-4 is not that. It is more like structural glue. Most proteases act directly on their targets, but BFT appears to need a separate receptor first, and the team could not find another toxin known to work this way.

To prove the two really bind, the Hopkins group teamed up with structural biologists at the Molecular Biology Institute of Barcelona. Their lab experiments showed one toxin molecule pairing with one claudin-4 molecule in a tight complex. Even AlphaFold, the AI structure predictor, has not yet fully resolved how the two fit together.

A decoy that fooled the toxin

Knowing the lock gave the team an idea: offer the toxin a fake one. They built a soluble protein carrying claudin-4 sequences, a molecular decoy meant to lure BFT away from the colon wall. In experiments with Min Dong's lab at Harvard Medical School, the toxin latched onto the decoys instead, and mice were protected from BFT damage.

White said the approach could be improved with small molecules or other biologics that have better drug properties. The team is now exploring which molecular strategies might work best, as reported by The Hindu BusinessLine.

What this does and does not mean

Before anyone panics about their microbiome, the limits matter. The mouse tests showed protection from tissue damage, not prevention of colorectal cancer in people. Safety and effectiveness in humans are still unknown, and building a real treatment takes years of work.

Still, the finding matters for a bigger reason. Colorectal cancer is increasingly showing up in younger adults, and this research points to a new way to think about prevention: block the toxin at the door instead of repairing the damage afterward. Senior author Sears said understanding how bacterial toxins work could open doors for detection and therapy of conditions including diarrhea, colorectal cancer and bloodstream infections.

For now, the practical advice has not changed. Keep up with screening when it is recommended and pay attention to symptoms. For more stories like this, browse the science section and the health section on GenZ NewZ.